NHS England Evidence review: Prevention and Management of Delayed Haemolytic Transfusion Reactions and Hyperhaemolysis in patients of all ages with haemoglobinopathies
NHS England requests your views on a new commissioning policy statement regarding Rituximab and Eculizumab are recommended to be considered as a treatment option through routine commissioning for delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies within the criteria set out in the draft policy proposition.
A final decision as to whether Rituximab and Eculizumab will be routinely commissioned will be made by NHS England following a recommendation from the Clinical Priorities Advisory Group.
As a key stakeholder, we wish to hear your views on these proposals before they are considered further by BHS England.
Attached are the following documents:
- Policy proposition 1821 Policy Proposition SHTest.pdf
- The evidence that informed this proposal 1821 Evidence Review Final.pdf
- Stakeholder response form 1821 RTX EC DHHTR HH PP response form.docx
Please note that in order for these responses to be processed we can only access responses that are submitted using the attached stakeholder response form.
Please could you nsure all responses are submitted by 30 September 2019 to the following email address: email@example.com
Thank you for your continued support
Blood & Infection Programme of Care